Skip to main content

GeraClinic / NHS cancer waiting times / NHS Cheshire And Merseyside ICB

NHS Cheshire And Merseyside ICB: NHS Cancer Waiting Times

In April 2026, 76.9% of cancer patients in NHS Cheshire And Merseyside ICB started treatment within 62 days of urgent referral — 7.1 percentage points above the England average. Gera Cancer Pathway Pressure Index: 61.2/100 (high pathway pressure). Official NHS England data.

Reference period: April 2026(NHS England Cancer Waiting Times, published June 2026) · updated monthly · Open Government Licence v3.0 · England

What is the NHS cancer waiting time in NHS Cheshire And Merseyside ICB?

As of April 2026, 76.9% of cancer patients in NHS Cheshire And Merseyside ICB started treatment within 62 days of urgent referral — 7.1 percentage points above the England average (NHS target: 85%) — covering 1,386 patients, per NHS England Cancer Waiting Times data published June 2026. Gera re-dates this monthly.

Source:NHS England Cancer Waiting Times (CWT CRS) — ICB Sub-Location extract·as of April 2026updated monthly (last: )
Gera Cancer Pathway Pressure Index61.2 / 100NHS Cheshire And Merseyside ICB — high pathway pressureHow this index is calculated

The GCPPI for NHS Cheshire And Merseyside ICB = (1 − 76.9% / 100) × 13,891 FDS referrals = raw pressure 3209, normalised to 61.2/100. Rank 8 of 36 ICBs (rank 1 = most pressure). See methodology.

NHS cancer waiting times figures for NHS Cheshire And Merseyside ICB (April 2026)
MeasureNHS Cheshire And Merseyside ICBWhat it means
62-day standard met76.9%NHS target: 85%
28-day FDS met77.2%NHS target: 75%
Patients in 62-day pathway1,386All four 62-day sub-pathways
FDS referral volume13,891Faster Diagnosis Standard demand
Gera Pressure Index (GCPPI)61.2 / 100high pathway pressure
Pathway pressure rank8 / 36Rank 1 = most pressure in England
62-day pathway breakdown for NHS Cheshire And Merseyside ICB (April 2026)
PathwayPatients62-day metStandard
Urgent Suspected Cancer76070.3%Missed
Screening9178.0%Missed
Consultant Upgrade53086.2%Met
Breast Symptomatic580.0%Missed

Check your area's cancer pathway pressure

Compare NHS Cheshire And Merseyside ICB with other ICBs — real NHS data, updated monthly

In NHS Cheshire And Merseyside ICB, 76.9% of cancer patients started treatment within 62 days of urgent referral in April 2026 — 7.1 percentage points above the England average. The NHS standard is 85%.

62-day standard met

76.9%

NHS target: 85%

28-day FDS met

77.2%

Faster Diagnosis Standard (75%)

Gera Pressure Index

61.2 / 100

high pathway pressure

1,386 patients reached a 62-day treatment decision in this ICB (April 2026); England total: 27,522.

Pathway breakdown (62-day, April 2026):

PathwayPatientsMet standard
Urgent Suspected Cancer76070.3%
Screening9178.0%
Consultant Upgrade53086.2%
Breast Symptomatic580.0%

NHS Cheshire And Merseyside ICB is at 76.9% on the 62-day standard — below the NHS 85% target. GeraClinic can connect you to a cancer specialist quickly while you await NHS assessment.

Book a cancer consultation

Compare cancer waiting times in other areas

Sorted by Gera Cancer Pathway Pressure Index (highest pressure first).

NHS Cheshire And Merseyside ICB cancer waiting times: FAQs

What is the NHS cancer 62-day waiting time in NHS Cheshire And Merseyside ICB?
In April 2026, 76.9% of cancer patients in NHS Cheshire And Merseyside ICB started treatment within 62 days of urgent referral — 7.1 percentage points above the England average. The NHS target is 85%. Data: NHS England Cancer Waiting Times.
What is the Gera Cancer Pathway Pressure Index for NHS Cheshire And Merseyside ICB?
The Gera Cancer Pathway Pressure Index (GCPPI) for NHS Cheshire And Merseyside ICB in April 2026 is 61.2/100 (high pathway pressure). It is computed as (1 − 62-day standard met rate) × referral volume, normalised across all 36 ICBs. NHS Cheshire And Merseyside ICB ranks 8 of 36 ICBs by pathway pressure.
How does NHS Cheshire And Merseyside ICB compare on the 28-day Faster Diagnosis Standard?
In April 2026, 77.2% of patients in NHS Cheshire And Merseyside ICB received a cancer diagnosis or ruling-out within 28 days (NHS FDS target: 75%). NHS Cheshire And Merseyside ICB processed 13,891 FDS referrals in this period, per NHS England Cancer Waiting Times data.
Can I be seen privately while waiting for cancer assessment in NHS Cheshire And Merseyside ICB?
Yes. Being assessed or treated privately does not affect your NHS referral. GeraClinic can connect you to a UK-registered cancer specialist. You keep your place on the NHS list and can access a private consultation simultaneously.
What are the main cancer pathways in NHS Cheshire And Merseyside ICB?
The NHS 62-day standard in NHS Cheshire And Merseyside ICB covers four pathways: Urgent Suspected Cancer (the primary 2-week-wait route), Screening (referrals from NHS screening programmes), Consultant Upgrade (reclassification onto the 62-day pathway by a clinician), and Breast Symptomatic (non-2WW breast referrals). In April 2026, NHS Cheshire And Merseyside ICB recorded 1,386 patients across all four pathways.

NHS Cheshire And Merseyside ICB is below the NHS 85% cancer target

Only 76.9% of cancer patients in NHS Cheshire And Merseyside ICB met the 62-day standard in April 2026 (NHS target: 85%). GeraClinic can connect you to a UK-registered cancer specialist quickly — you keep your NHS referral while getting faster private assessment.

Data and methodology

Figures for NHS Cheshire And Merseyside ICB are aggregated from the real per-sub-location count rows in NHS England's April 2026 Cancer Waiting Times ICB Sub-Location extract. Each sub-location code (e.g. multiple [ICB sub-location codes, NHS ODS]) is mapped to its parent ICB via the NHS Organisation Data Service and summed for both the 62-day Combined and 28-day FDS standards. Percentages are re-derived from summed numerators and denominators — not averaged. The Gera Cancer Pathway Pressure Index = (1 − 62-day met rate) × referral volume, normalised 0–100. No estimates or invented numbers. See full methodology.

Contains public sector information published by NHS England and licensed under the Open Government Licence v3.0.